GIM
RPRX icon

Generate Investment Management’s Royalty Pharma RPRX Stock Holding History

Generate Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-396,342
Closed -$12M – 88
2024
Q1 		$12M Sell
396,342
-82,906
-17% -$2.44M 0.87% 37
2023
Q4 		$13.5M Buy
+479,248
New +$13.2M 1.16% 33

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Generate Investment Management's RPRX Position: Q2 2024 in Review

Generate Investment Management sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 396,342 shares — an estimated $12M sold.

Generate Investment Management first reported a position in RPRX in Q4 2023 and held it in 2 quarters. The position peaked at $13.5M in Q4 2023. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

  • Generate Investment Management reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
  • Generate Investment Management sold 396,342 Royalty Pharma shares in Q2 2024, an estimated $12M.
  • Generate Investment Management first reported a position in Royalty Pharma in Q4 2023 and held it in 2 quarters.
  • Generate Investment Management's Royalty Pharma position peaked at $13.5M in Q4 2023.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Generate Investment Management's 13F filing for Q2 2024, filed 1 Aug 2024.